Meimei Jiang

Changsha, 410082, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Huzhang-Xiangbaji compounds enhance the repair of meniscal cartilage by inhibiting ferroptosis and inflammatory microenvironment.

Huzhang-Xiangbaji compounds enhance the repair of meniscal cartilage by inhibiting ferroptosis and inflammatory microenvironment.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: December 09, 2025

WITHDRAWN: Multi-omics integration deciphers immune-metabolic heterogeneity in CRC: A prognostic model and therapeutic strategies targeting ANGPTL4/FABP4/RBP7.

WITHDRAWN: Multi-omics integration deciphers immune-metabolic heterogeneity in CRC: A prognostic model and therapeutic strategies targeting ANGPTL4/FABP4/RBP7.

Journal: Computers in biology and medicine
Published: July 01, 2025

SIRT6-Mediated Regulation of TFAM: A Central Mechanism Connecting Nuclear and Mitochondrial Transcriptional Processes and Mitophagy.

SIRT6-Mediated Regulation of TFAM: A Central Mechanism Connecting Nuclear and Mitochondrial Transcriptional Processes and Mitophagy.

Journal: International journal of biological sciences
Published: June 20, 2025

Unraveling the miR-144-3p/PUMA pathway: a novel regulator of FDX1-mediated cuproptosis in colorectal cancer.

Unraveling the miR-144-3p/PUMA pathway: a novel regulator of FDX1-mediated cuproptosis in colorectal cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)
Published: April 16, 2025

Immunogenic cuproptosis in cancer immunotherapy via an in situ cuproptosis-inducing system.

Immunogenic cuproptosis in cancer immunotherapy via an in situ cuproptosis-inducing system.

Journal: Biomaterials
Published: December 14, 2024

LncRNA CARMN m6A demethylation by ALKBH5 inhibits mutant p53-driven tumour progression through miR-5683/FGF2.

LncRNA CARMN m6A demethylation by ALKBH5 inhibits mutant p53-driven tumour progression through miR-5683/FGF2.

Journal: Clinical and translational medicine
Published: February 05, 2024

SIRT6 suppresses colon cancer growth by inducing apoptosis and autophagy through transcriptionally down-regulating Survivin.

SIRT6 suppresses colon cancer growth by inducing apoptosis and autophagy through transcriptionally down-regulating Survivin.

Journal: Mitochondrion
Published: August 30, 2023

Targeting AKT induced Ferroptosis through FTO/YTHDF2-dependent GPX4 m6A methylation up-regulating and degradating in colorectal cancer.

Targeting AKT induced Ferroptosis through FTO/YTHDF2-dependent GPX4 m6A methylation up-regulating and degradating in colorectal cancer.

Journal: Cell death discovery
Published: March 30, 2023

Inhibition of AKT induces p53/SIRT6/PARP1-dependent parthanatos to suppress tumor growth.

Inhibition of AKT induces p53/SIRT6/PARP1-dependent parthanatos to suppress tumor growth.

Journal: Cell communication and signaling : CCS
Published: January 09, 2022

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway.

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway.

Journal: International journal of biological sciences
Published: September 17, 2021

Targeting ERK induced cell death and p53/ROS-dependent protective autophagy in colorectal cancer.

Targeting ERK induced cell death and p53/ROS-dependent protective autophagy in colorectal cancer.

Journal: Cell death discovery
Published: May 17, 2021
Showing 1-11 of 11

Last Updated: 09/26/2026